Evidence map›Paper›PMID 38127178›Full record

ArticleMolecular biology reports2023

Current non-invasive strategies for brain drug delivery: overcoming blood-brain barrier transport.

Xiaoxiao Zheng, Jingyao Yang, Yiwei Hou, Yong Fang, Kaiyu Wu, Yanna Song, Kangding Liu, Jie Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Engineered Antibodies as Cancer Radiotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoxiao Zheng *Department of Neurology, Neuroscience Center, First Hospital of Jilin University, Xinmin Street 1#, Changchun, 130021, China.
Jingyao Yang *School of Basic Medical Sciences, Institute of Physiology, Shanxi Medical University, Taiyuan, China.
Yiwei Hou *Department of Neurology, Neuroscience Center, First Hospital of Jilin University, Xinmin Street 1#, Changchun, 130021, China.
Yong FangDepartment of Neurology, Neuroscience Center, First Hospital of Jilin University, Xinmin Street 1#, Changchun, 130021, China.
Kaiyu WuDepartment of Neurology, Neuroscience Center, First Hospital of Jilin University, Xinmin Street 1#, Changchun, 130021, China.
Yanna SongDepartment of Neurology, Neuroscience Center, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Kangding LiuDepartment of Neurology, Neuroscience Center, First Hospital of Jilin University, Xinmin Street 1#, Changchun, 130021, China. liukd@jlu.edu.cn.
Jie ZhuDepartment of Neurology, Neuroscience Center, First Hospital of Jilin University, Xinmin Street 1#, Changchun, 130021, China. jzhu@jlu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe blood-brain barrier (BBB) is a complex and dynamic structure that serves as a gatekeeper, restricting the migrations of most compounds and molecules from blood into the central nervous system (CNS). The BBB plays a crucial role in maintaining CNS physiological function and brain homeostasis. It can protect the CNS from the entrance of toxic and infectious agents, however, it also restricts the drug permeation into brain to play a therapeutic role. The BBB has been the biggest limiting hurdle to medications entering the brain excluding from the brain about 100% of large-molecule and more than 98% of all small-molecule neurotherapeutics. As a result, it is of inability for drug molecule to reach requisite concentrations within the brain.

objectiveWith the aim of enhancing drug permeability and efficacy, a variety of strategies have been developed: invasive approaches, such as intraarterial delivery, intrathecal delivery, or administrating directly the drug intraventricularly and intracerebrally; non-invasive approaches that take advantage of innate BBB functions, using prodrugs, focused ultrasound, intranasal administration or nanotechnology.

conclusionsHere we mainly review recent developments and challenges related to non-invasive BBB-crossing techniques, whose benefits include higher efficacy, easier application, less treatment burden, better patient acceptability, and adherence. Additionally, we also analyze the potential of non-invasive methods in the treatment of CNS disorders and render them as a most suitable platform for the management of neurological diseases.

Indexed as

Blood-Brain BarrierBrainCentral Nervous SystemDrug Delivery SystemsHomeostasisHumansBlood–brain barrierCentral nervous systemMedication delivery techniquesNon-invasive approaches

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.